Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Diehl, V ^a   Fuchs, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LEUKOPENIA; LUNG DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARYNX DISEASE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; GENETICS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36049038568     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm297     Document Type: Conference Paper

References (20)

1. Sieber M, Franklin J, Tesch H et al. Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) trial HD7. Blood 2002; 100: 341a.
2. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-4244.
3. Horning SJ, Hoppe RT, Mason J et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal, lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15: 1736-1744.
4. Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 1996; 7 (Suppl 4): 105-108.
5. Sieber M, Tesch H, Pfistner B et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: Final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002; 20: 476-484.
6. Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patents with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-3608.
7. Fermé C, Eghbali H, Hagenbeek A. MOPP/ABV (M/A) hybrid irradiation in unfavorable supradiaphragmatic clinical stages I-II HD: Comparison or three treatment modalities, preliminary results of the EORTC-GELA H8-U randomized trial in 995 patents. Blood 2000; 96: 576a.
8. Bonadonna G, Zucall R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-259.
9. Jones SE, Haut A, Weick JK et al. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study, Cancer 1983; 51: 1339-1347.
10. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 1421-1430.
11. Glick JH, Young ML, Harrington D et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol 1998; 16: 19-26.
12. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of AND and MOPP/AI3V hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 21. 2003; 607-614.
13. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
14. Gobbi PG, Levis A, Cisesi T et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23: 9198-9207.
15. Radford JA Rohatiner AZ, Ryder WT et al. ChIVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988-2994.
16. Diehl V, Franklin J, Preundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
17. Diehl V, Brilliant C, Franklin J et al. BEACOPP Chemotherapy for Advanced Hodgkin's Disease: Results of Further Analyses of the HD9- and HD12-Trials of the German Hodgkin Study Group (GHSG). Blood 2004; 104: 307a.
18. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1996; 7 (Suppl 4): 95-98.
19. Sieber M, Bredenfeld H, Josting A et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 1734-1739.
20. Aleman BM, Raemaekers JM, Tirelli U et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-2406.